Clinical Trials
3 trialsNCT05481437 2026-04-13
A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma
Takeda
Recruiting
NCT04213209 2024-09-27
Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"
Takeda
Completed
NCT02139592 2020-07-13
Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"
Takeda
Completed